Skip to Main Content
Rapport Therapeutics Rapport Therapeutics
Menu Button

news

Press releases

Rapport Therapeutics Appoints Chief Operating Officer and Scientific Advisory Board Member

BOSTON and SAN DIEGO – September 7, 2023 – Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of…

Read Rapport Therapeutics Appoints Chief Operating Officer and Scientific Advisory Board Member Now
Rapport Therapeutics Raises $150 Million in Series B Funding Round and Announces Key Board Appointments to Further Advance Precision Neuromedicine Platform

Funding to support ongoing clinical programs in seizure and psychiatric disorders and precision neuromedicine discovery platform Raymond Kelleher, M.D., Ph.D.,…

Read Rapport Therapeutics Raises $150 Million in Series B Funding Round and Announces Key Board Appointments to Further Advance Precision Neuromedicine Platform Now
Rapport Therapeutics Names Scientific Advisory Board

Board to be co-chaired by two Nobel laureates Members include world-renowned experts in ion channel signaling, seizure disorders and the…

Read Rapport Therapeutics Names Scientific Advisory Board Now
Rapport Therapeutics Launches with $100 Million to Transform the Treatment of Neurological Disease through the Discovery and Development of Precision Therapies

Series A financing led by Third Rock Ventures with participation from ARCH Venture Partners and Johnson & Johnson Innovation-JJDC, Inc….

Read Rapport Therapeutics Launches with $100 Million to Transform the Treatment of Neurological Disease through the Discovery and Development of Precision Therapies Now